Consolidated Statements of Income (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Net revenue	$ 687,864	$ 558,588	$ 484,732
Operating expenses:
Cost of revenue	262,785	177,339	156,866
Research and development	146,930	126,423	110,180
Selling, general and administrative	264,958	171,753	159,617
Total operating expenses	674,673	475,515	426,663
Income from operations	13,191	83,073	58,069
Legal settlement	0	0	17,984
Co-promotion and profit share income	17,383	10,000	0
Interest expense	(15,531)	(8,005)	0
Other income	1,577	1,140	1,790
Income before income taxes	16,620	86,208	77,843
(Provision) benefit for income taxes	(1,360)	(35,038)	50,034
Net income	15,260	51,170	127,877
Net loss attributable to non-controlling interest	252	84	0
Net income attributable to The Medicines Company	$ 15,512	$ 51,254	$ 127,877
Earnings per common share attributable to The Medicines Company:
Basic (USD per share)	$ 0.27	$ 0.96	$ 2.39
Diluted (USD per share)	$ 0.25	$ 0.93	$ 2.35
Weighted average number of common shares outstanding:
Basic (shares)	58,096	53,545	53,496
Diluted (shares)	62,652	55,346	54,407